Researchers at the US University of Pennsylvania’s Perelman School of Medicine have developed a new blood test to measure the body’s immune system response to the Covid-19 vaccine.
The first-of-its-kind test can assess antibody and T-cell responses to the Covid-19 vaccine in multiple sclerosis (MS) patients who have undergone immune-suppressing anti-CD20 (aCD20) treatment.
It provides a clear picture of the immune response and can be integrated into a patient’s electronic health record to help clinicians provide counsel.
